Elliot Norry, the Chief Medical Officer of $ADAP ($ADAP), sold 5,584 shares of the company on 01-17-2025 for an estimated $3,243. We received data on the trade from a ...

Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) shares are trading higher by 15.8% to $1.17 during Friday’s session after the company and Galapagos entered a clinical collaboration to license ...

ADAPTIMMUNE THERAPEUTICS ($ADAP) posted quarterly earnings results on Tuesday, May 13th. The company reported earnings of -$0.18 per share, missing estimates of -$0. ...

Seeing as Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADP) has experienced bearish sentiment from the aggregate hedge fund industry, logic holds that there lies a certain “tier” of money managers that ...

Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) had its price objective cut by stock analysts at Scotiabank from $3.15 to $1.40 in a report issued on Friday,Benzinga reports. The brokerage ...

Adaptimmune Therapeutics is focused on late-stage development of cell therapy for cancer, particularly in sarcoma management. Pipeline updates include progress on afami-cel for soft tissue sarcomas ...

Adaptimmune Therapeutics plc (NASDAQ:ADAP – Free Report) – Analysts at Zacks Small Cap issued their Q1 2025 EPS estimates for Adaptimmune Therapeutics in a report released on Tuesday, March 25th.

Adaptimmune Therapeutics (NASDAQ:ADAP) announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for its lead candidate Tecelra (afami-cel) as a treatment for a type of ...